Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Return on Equity (2018 - 2025)

Historic Return on Equity for Autolus Therapeutics (AUTL) over the last 5 years, with Q3 2025 value amounting to 0.73%.

  • Autolus Therapeutics' Return on Equity fell 2000.0% to 0.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.73%, marking a year-over-year decrease of 2000.0%. This contributed to the annual value of 0.82% for FY2024, which is 2000.0% up from last year.
  • Per Autolus Therapeutics' latest filing, its Return on Equity stood at 0.73% for Q3 2025, which was down 2000.0% from 0.63% recorded in Q2 2025.
  • Autolus Therapeutics' Return on Equity's 5-year high stood at 0.42% during Q2 2024, with a 5-year trough of 184.68% in Q2 2022.
  • Over the past 4 years, Autolus Therapeutics' median Return on Equity value was 0.64% (recorded in 2024), while the average stood at 23.13%.
  • Over the last 5 years, Autolus Therapeutics' Return on Equity had its largest YoY gain of 1840600bps in 2023, and its largest YoY loss of -7800bps in 2023.
  • Autolus Therapeutics' Return on Equity (Quarter) stood at 0.65% in 2022, then plummeted by -120bps to 1.43% in 2023, then soared by 66bps to 0.49% in 2024, then crashed by -51bps to 0.73% in 2025.
  • Its Return on Equity was 0.73% in Q3 2025, compared to 0.63% in Q2 2025 and 0.6% in Q1 2025.